Keith Gottesdiener - Concepedia

Author

Keith Gottesdiener

Merck & Co., Inc., Rahway, NJ, USA (United States)ORCID

Also Known As

A. B. Kanstrup, Ayers, K.L., Gottesdiener K, K GOTTESDIENER, K Gottesdiener, K M Gottesdiener, K. GOTTESDIENER, K. Gottesdiener, K. M. Gottesdiener, K., Gottesdiener

156

Publications

11.5K

Citations

H-Index

176

Concepts

All Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)United States Military Academy Columbia University Jazz Pharmaceuticals (United States)Cornell University

About

Keith Gottesdiener is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	37	66	6.5K
2	Health Sciences	12	12	1.5K
3	Natural Sciences	12	12	677
4	Public Health	2	2	169
5	Engineering	1	1	40

Keith Gottesdiener

113

Publications

11K

Citations

H-Index

Page 1

	Year	Citations
Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial Susan Buchbinder, Devan V. Mehrotra, Ann Duerr, The Lancet VaccinationTest-of-concept TrialTreatment And PreventionImmunologyVaccine Trial	2008	1.7K
Induction of Adipocyte Complement-Related Protein of 30 Kilodaltons by PPARγ Agonists: A Potential Mechanism of Insulin Sensitization Terry P. Combs, John A. Wagner, Joel P. Berger, Endocrinology	2002	566
Effect of Single Oral Doses of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on Incretin and Plasma Glucose Levels after an Oral Glucose Tolerance Test in Patients with Type 2 Diabetes Gary Herman, Arthur Bergman, Catherine Stevens, The Journal of Clinical Endocrinology & Metabolism	2006	498
Proopiomelanocortin Deficiency Treated with a Melanocortin-4 Receptor Agonist Peter Kühnen, Karine Clément, Susanna Wiegand, New England Journal of Medicine Metabolic DisorderPharmacotherapyGlucocorticoidObesityMetabolic Syndrome	2016	462
[<sup>18</sup>F]MK-9470, a positron emission tomography (PET) tracer for<i>in vivo</i>human PET brain imaging of the cannabinoid-1 receptor H. Donald Burns, Koen Van Laere, Sandra Sanabria Bohórquez, Proceedings of the National Academy of Sciences	2007	311
MC4R agonism promotes durable weight loss in patients with leptin receptor deficiency Karine Clément, Heike Biebermann, I. Sadaf Farooqi, Nature Medicine ObesityMetabolic SyndromeNutritionLeptin Receptor DeficiencyEnergy Homeostasis	2018	294
Evaluation of a melanocortin-4 receptor (MC4R) agonist (Setmelanotide) in MC4R deficiency Tinh‐Hai Collet, B. Dubern, Jacek Mokrosiński, Molecular Metabolism	2017	286
Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies Rajesh Krishna, Matt S. Anderson, Arthur Bergman, The Lancet Metabolic SyndromeHypertensionHealthy IndividualsLipid DisorderCardiovascular Disease	2007	276
Antagonism of the prostaglandin D <sub>2</sub> receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans Kang Cheng, Tsuei-Ju Wu, Kenneth K. Wu, Proceedings of the National Academy of Sciences InflammationMolecular PharmacologySignal TransductionMolecular PhysiologyMedicine	2006	268
Effect of Sitagliptin, a Dipeptidyl Peptidase‐4 Inhibitor, on Blood Pressure in Nondiabetic Patients With Mild to Moderate Hypertension Goutam C. Mistry, Andrea Maes, Kenneth C. Lasseter, The Journal of Clinical Pharmacology	2008	211

Page 1